Three trials with short-acting GLP-1RAs, exenatide and lixisenatide, showed slowed motor decline, though longer-acting formulations have not replicated this
Thats because a variety of factors can impact if, and which, side effects someone may experience
Apogee Therapeutics's has zumilokibart (APG777) is an antiIL-13 antibody being developed for (moderate to severe) atopic dermatitis (AD) and other inflammatory diseases
Injectable hydrogels Injectable hydrogels are stimuli-responsive polymeric networks designed to undergo sol-to-gel transitions under physiological conditions, thereby enabling localized and sustained drug delivery via minimally invasive SC administration [44]
In 2025, the company reported a strong +11.05% YoY revenue growth, driven by a favorable product mix: Eylea ($3.65B) remained a key ophthalmology contributor despite competitive pressure, Nubeqa ($2.8B) emerged as a major growth driver with expanding adoption in prostate cancer, and Xarelto ($2.75B) continued to generate significant revenue, although facing gradual decline due to patent expiries and generic competition
Quick Answer: Semaglutide causes diarrhea by activating GLP-1 receptors in the gastrointestinal tract, which alters gut motility, slows gastric emptying, and disrupts normal digestive processes